Physician profile
Matthew Glover
NPI 1477949675
$7,912.97
in general payments reported to CMS, 2019-2025
32 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $25.02 · 2021: $654 · 2022: $1,784 · 2023: $1,055 · 2024: $2,540 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,004.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,650.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $564.89 | 2021-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $491.31 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $416.04 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $316.63 | 2019-2025 | |
| Gilead Sciences, INC. | $314.13 | 2021-2025 | |
| Genzyme Corporation | $215.24 | 2023-2025 | |
| Redhill Biopharma INC. | $185.55 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Lilly USA, LLC | $166.52 | 2024-2025 | Omvoh, Zepbound |
| Aimmune Therapeutics, INC. | $159.99 | 2024-2025 | Zenpep |
| Boston Scientific Corporation | $149.40 | 2022 | |
| Intercept Pharmaceuticals, INC. | $129.77 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.52 | 2021 | |
| Janssen Scientific Affairs, LLC | $120.11 | 2021 | |
| Nestle Healthcare Nutrition INC. | $108.47 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $101.47 | 2023-2024 | Ibsrela |
| Erbe USA INC | $99.00 | 2019 | |
| Braintree Laboratories, INC. | $83.68 | 2021-2024 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $67.86 | 2021-2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $66.98 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $61.04 | 2022-2023 | |
| Qol Medical, LLC | $55.10 | 2022-2024 | Sucraid |
| Celgene Corporation | $42.34 | 2022-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $34.92 | 2025 | Voquezna |
| Lucid Diagnostics INC. | $29.72 | 2023 | |
| Mallinckrodt Hospital Products INC. | $27.77 | 2024 | Terlivaz |
| Sandoz INC. | $26.55 | 2024 | Hyrimoz |
| Biocon Biologics INC | $24.35 | 2025 | Yesintek |
| Madrigal Pharmaceuticals | $23.68 | 2025 | Rezdiffra |
| Celltrion USA INC. | $22.44 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $19.84 | 2022 | |
| Medtronic, INC. | $12.76 | 2023 | Interstim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Glover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.